Dendreon (DNDN) Completes Submission of Biologics License Application for PROVENGE
More News related to DNDN
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- Dendreon Announces Webcast Presentation at 12th Annual BIO CEO and Investor Conference
- Mentor Capital Cancer Index Start Oversubscribed
- Cowen Starts Dendreon (DNDN) at Outperform
- Mentor Capital Chairman Highlights $0.91/Share Non-GAAP Gains from Cancer Portfolio Appreciation
More News related to FDA
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
- Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb
- Dynavax Tech (DVAX) Initiates HEPLISAV Phase 3
Dendreon (Nasdaq: DNDN) Completes Submission of Biologics License Application for PROVENGE
Related Categories
FDAHot List
Stocks Mentioned
+0.54Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
